
Please try another search
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company’s ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Claus van der Velden | 50 | 2018 | Lead Independent Director |
Jiong Ma | 59 | 2021 | Independent Chairman |
Tangui Nicolas Maurice | - | - | Member of the Scientific Advisory Board |
Christopher U. Missling | 57 | 2013 | President, CEO, Secretary & Director |
Paul S. Aisen | - | 2011 | Member of the Scientific Advisory Board |
Athanasios Skarpelos | 57 | 2013 | Independent Director |
Norman Relkin | - | 2014 | Member of the Scientific Advisory Board |
Peter Donhauser | 58 | 2017 | Independent Director |
Steffen Thomas | 59 | 2015 | Independent Director |
Ottavio Arancio | - | 2013 | Member of the Scientific Advisory Board |
Jacqueline A. French | - | 2015 | Member of the Scientific Advisory Board |
Corinne Lasmézas | - | 2015 | Member of the Scientific Advisory Board |
Dag Aarsland | - | 2018 | Member of Scientific Advisory Board |
Marwan Noel Sabbagh | 58 | 2023 | Member of Scientific Advisory Board |
Timo Grimmer | - | 2022 | Member of Scientific Advisory Board |
Audrey Gabelle | - | 2025 | Member of Scientific Advisory Board |
Daniel Weintraub | - | 2016 | Member of the Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review